The presentation of new and supportive data on Galapagos' CAR-T therapy platform at a significant conference could positively impact investor sentiment. The data underscores the platform's potential in treating severe hematologic cancers, which could lead to increased interest from the medical community and investors. The emphasis on the platform's unique manufacturing capabilities and the robustness of the CAR-T cells it produces suggests a competitive edge in the CAR-T therapy market. This could translate into positive short-term price movement as the market reacts to the potential for future regulatory approvals and market penetration.